Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 12,801–12,900 of 15,747
An Overview of COVID-19 and Its Vaccines
Rehman, N., & Pandey, A. (2021) · Biology Bulletin Reviews · doi:10.1134/s2079086421070069 · Cited by 2
Assessment of Immune Correlates of Protection via Controlled Vaccine Efficacy and Controlled RiskPreprint
Gilbert, P. B., Fong, Y., & Carone, M. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2107.05734 · Cited by 2
Ferawati, K., Liew, K., Aramaki, E., & Wakamiya, S. (2022) · doi:10.2196/preprints.39504 · Cited by 1
Áñez, G., Kotloff, K. L., Gay, C. L., Nelson, J., Dunbar, H., Cloney-Clark, S., McGarry, A., Woo, W., Cho, I., Plested, J. S., et al. (2023) · medRxiv · doi:10.1101/2023.05.08.23289670 · Cited by 2
“In addition, we performed an ad hoc analysis of humoral immune responses in a subset of participants without evidence of previous SARS-CoV-2 infection who received NVX-CoV2373 (N = 119) and self-reported as people living with HIV(PLWH), and whose HIV infection was well-controlled by stable antiretroviral therapy (HIV…”
MethodOgihara, R., Matsuura, M., Ishida, T., Morikubo, H., Mitsui, T., Saito, D., Miyoshi, J., Shibahara, J., Sunami, E., & Hisamatsu, T. (2025) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-025-02136-9 · Cited by 1
“In randomized clinical trials and real-world cohort studies, common adverse events of SARS-CoV-2 vaccinations include localized injection site reactions (e.g., redness, swelling, pain), fever, fatigue, and headache; however, serious adverse events are rare [3–5].”
Infectiousness in omicron variant strain and bA.2 variant in JapanPreprint
Kurita, J., Sugawara, T., & Ohkusa, Y. (2021) · medRxiv · doi:10.1101/2021.06.20.21259209 · Cited by 1
Bourrier, M., Deml, M. J., & Mahdavian, F. (2022) · doi:10.31265/usps.254 · Cited by 1
Avances en el desarrollo y el uso de las vacunas contra el SARS-CoV-2
Lanata, C. F., Ecker, L., Cornejo, R., & Gómez-Merino, A. I. (2021) · ACTA MEDICA PERUANA · doi:10.35663/amp.2021.381.2092 · Cited by 1
“Vacuna Nombre/ Laboratorio Eficacia COVID-19 total Eficacia COVID-19 severo Autoridad Regulatoria Efectividad Eficacia Infecciones asintomáticas Precalificada OMS / UNICEF mRNA Pfizer 95% 100% FDA /EMA 80-90% 86-91% Si mRNA Moderna 94% 96% FDA /EMA NC 82-91% Pendiente mRNA CureVac Pend Pend EMA Pend Pend No presentada…”
BackgroundInfluentialVaxLab: integrated platform for rapid multistrategy mRNA vaccine design
Kim, J., Han, Y., Kwon, C. Y., & Chang, H. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01637-y · Cited by 2
Goepfert, P. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179149 · Cited by 1
“Both Pfizer-BioNTech NT162b2 and Moderna mRNA-1273 vaccines demonstrated remarkable efficacy and safety in large-scale clinical trials (2, 3).”
BackgroundZhang, Z., Wang, Y., Zhao, J., Liu, L., Ran, P., Yang, S., Xu, W., & Fu, G. (2024) · International Archives of Allergy and Immunology · doi:10.1159/000542281 · Cited by 1
Effects of vaccination on COVID-19 infection symptoms in multiple sclerosis patients
Sharifi, P., Rezaeimanesh, N., Moradi, A., & Moghadasi, A. N. (2024) · eNeurologicalSci · doi:10.1016/j.ensci.2024.100511 · Cited by 1
Applications of Spray-Dried Vaccines
Arpagaus, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-24323-3_6 · Cited by 2
The Health of Pregnant Women and Their Unborn Children– Neglected in Vaccine Development
Selley, P., & Healy, D. (2025) · Birth Defects Research · doi:10.1002/bdr2.2483 · Cited by 1
Enilama, O., Yau, K., Er, L., Atiquzzaman, M., Oliver, M. J., Romney, M. G., Leis, J. A., Abe, K. T., Qi, F., Colwill, K., et al. (2024) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581231224127 · Cited by 1
“10,11 12-15 In addition, most of these studies looked at the response to 2 doses and were conducted prior to the emergence of some of the more novel variants of concerns, including Omicron (B. 1.1.529).”
BackgroundInfluentialGroß-Albenhausen, E., Weier, A., Velten, M., Heider, T., Chunder, R., & Küerten, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254128 · Cited by 2
Undiagnosed COVID-19 in households with a child with mitochondrial diseasePreprint
Gordon‐Lipkin, E. M., Marcum, C. S., Kruk, S., Thompson, E., Kelly, S., Kalish, H. R., Sadtler, K., & McGuire, P. J. (2022) · medRxiv · doi:10.1101/2022.03.21.22272358 · Cited by 2
Koblas, T., Bittenglová, K., Abaffy, P., Zacharovová, K., Girman, P., Valihrach, L., Kříž, J., & Saudek, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.21.746224 · Cited by 1
Petrovsky, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179459 · Cited by 1
Tachycardia following Pfizer-BioNTech COVID-19 vaccine
Martins‐Filho, P. R. (2023) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.11.013 · Cited by 1
Antibody responses to known and unknown SARS-CoV-2 infections after mRNA vaccine boosterPreprint
Demonbreun, A. R., Sancilio, A., Vaught, L. A., Reiser, N. L., Pesce, L. L., Sode, E. P., Mustanski, B. S., D’Aquila, R. T., McNally, E. M., & McDade, T. W. (2022) · medRxiv · doi:10.1101/2022.05.06.22274719 · Cited by 1
Novel dendritic cell vaccine strategies
Munson, P. V., Butterfield, L. H., & Adamik, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823901-8.00003-0 · Cited by 2
Symptoms and Duration of the Menstrual Cycle and Vaccination against Coronavirus Disease (COVID-19)
AKPERBEKOVA, S. A. (2022) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs07.03.092 · Cited by 1
Patients avec cancers thoraciques et COVID-19 : au cœur de la tempête
Gounant, V., Brosseau, S., Soussi, G., Pluvy, J., Guezour, N., Vauchier, C., Brouk, Z., Namour, C., & Zalcman, G. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00121-x · Cited by 1
Rathee, S., Dayaramani, R. A., & Tekade, R. K. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10343-7 · Cited by 1
“India’s vaccination strategy also expanded to include innovative solutions like ZyCoV-D, a DNA-based vaccine, and iNCOVACC, a needle-free intranasal vaccine [26].”
Untung, T., Pandey, R., & Johansson, P. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100580 · Cited by 1
“However, Debrabant reported that the vaccine ’ s effectiveness in the study was 95 percent, which is similar to the effectiveness of the Pfizer BioNTech vaccine [31].”
Mathematical modeling of SARS-nCoV-2 virus in Tamil Nadu, South India
Shankaranarayanan, A., & Wei, H. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022527 · Cited by 2
Chakravorty, S. (2020) · The Physician · doi:10.38192/1.6.3.11 · Cited by 1
Harnessing Immunological Targets for COVID-19 Immunotherapy
Mehata, A. K., Viswanadh, M. K., Priya, V., Vikas, V., & Muthu, M. S. (2021) · Future Virology · doi:10.2217/fvl-2021-0048 · Cited by 1
What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
Silvestris, N. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103733 · Cited by 1
“BNT162b2 mRNA vaccine has offered acceptable safety and efficiency against COVID-19 [3,4].”
Kawai, N., Ikematsu, H., Bando, T., Lee, W. J., Matsuura, S., Maeda, T., Echizen, M., & Kawashima, T. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102728 · Cited by 1
Damour, A., Faure, M., Landrein, N., Ragues, J., Ardah, N., Dhaidel, H., Lafon, M., Wodrich, H., & Basha, W. (2024) · Vaccines · doi:10.3390/vaccines12050493 · Cited by 3
“The efficacy of these vaccines varied, with reported rates of protection between 70% and 95% in the respective phase III clinical trials [6–12].”
BackgroundLEVINE, H. D., Sepulveda-Beltran, P. A., Altamirano, D. S., Sabater, A. L., Dubovy, S. R., Flynn, H. W., & Amescua, G. (2021) · Cornea · doi:10.1097/ico.0000000000002897 · Cited by 2
Hamel, L., Poirier‐Gravel, F., Paré, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.23.614541 · Cited by 1
Cox, R. E., Parish, M., Oxencis, C. J., Mckenna, E., Thapa, B., & Chakrabarti, S. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i7.599 · Cited by 1
Sakaguchi, H., Hirano, D., Takemasa, Y., Hiwatari, Y., Yoshizawa, S., Shoji, Y., Saito, A., Umeda, C., Miwa, S., Ito, A., et al. (2026) · CEN Case Reports · doi:10.1007/s13730-026-01126-1 · Cited by 1
Nanotechnology-based approaches against COVID-19
Abolmaali, S. S., Alimardani, V., Farahavar, G., Najafi, H., Shafiee, M., Tanideh, N., Tamaddon, A. M., & Ahadian, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90792-7.00012-9 · Cited by 5
Baxter, V. K., Anderson, E. J., Taft-Benz, S., Olsen, K. S., Sambade, M. J., Gentry, K. M., Beck, W. A., Garness, J. A., Woods, A., Fini, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.22.481499 · Cited by 1
The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines
Barda, N., & Dagan, N. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.12.006 · Cited by 1
“This was never more evident as in research on Covid-19 vaccines, where invariably RCTs answered initial questions regarding vaccine blished by Elsevier Ltd.”
BackgroundInfluentialEarly Oxygen Treatment Measurements Can Predict COVID-19 Mortality: A Preliminary Study
Levi, Y., Yamin, D., Brandes, T., Shmueli, E., Patalon, T., Peretz, A., Gazit, S., & Nahir, B. (2022) · Healthcare · doi:10.3390/healthcare10061146 · Cited by 1
“Despite the recent development of effective vaccines, the coronavirus pandemic will likely continue to affect our lives in the years to come due to the emergence of new, highly transmissible mutant strains [27–29], the incomplete efficiency of the developed vaccines in the elderly [30] and high-risk populations, and t…”
BackgroundRiedmann, U., Sprenger, M., Ioannidis, J. P. A., & Pilz, S. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70135 · Cited by 1
Aydın, H., Berikol, G. B., Koçak, M., & Doğan, H. (2022) · Anadolu Kliniği Tıp Bilimleri Dergisi · doi:10.21673/anadoluklin.1061232 · Cited by 1
Clinical features and acute management of COVID-19 in children
Longbottom, K., Whittaker, E., & Penner, J. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10024320 · Cited by 1
Modeling, Estimation, and Optimal Control of Anti-COVID-19 Multi-dose Vaccine AdministrationPreprint
Scarabaggio, P., Carli, R., Cavone, G., Epicoco, N., & Dotoli, M. (2021) · doi:10.36227/techrxiv.16794724
SARS-CoV-2 vaccines from A to Z: A Review of the current challenges
Albalaty, J. M., Forsan, F. H., Awad, S., et al. (2023) · Global NEST Journal · doi:10.30955/gnj.004651 · Cited by 1
“Regarding cardiovascular diseases, the Pfizer-BioNTech vaccine caused some adverse events, including paroxysmal ventricular arrhythmia (Polack et al ., 2020).”
BackgroundInfluentialOccupational Toxicology in the Pharmaceutical Industry
Dolan, D. G., Bercu, J. P., Graham, J. C., & Barle, E. L. (2023) · Wiley eBooks · doi:10.1002/0471125474.tox112.pub3 · Cited by 2
Rau, K., von Heeringen, E., Bühler, N., Wagenpfeil, S., Becker, S. L., & Schneitler, S. (2023) · Vaccines · doi:10.3390/vaccines11071147 · Cited by 1
“In the first studies, these vaccines provided excellent protection against symptomatic and severe SARS-CoV-2 infection, COVID-19-related hospitalization, and death [7,9].”
BackgroundAbdallah, A. M., Ansari, H. R., Shuaib, M., Doudin, A., Yassine, H. M., Shah, S. S. U. D., Mir, F. A., Emara, M. M., Elzouki, A.-N. Y., & Cyprian, F. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-04837-0 · Cited by 1
Alergia a la vacuna Pfizer-BioNTech® demostrada mediante pruebas cutáneas
García, C. D. E., Macías-Robles, A. P., Grimaldo, R. M. C., Alonso, H. L. C., Alcalá, M. B., Nepomuceno, A. R., Amaya, D. E., Hernández, K. G. C., Díaz, B. B., & Campos-Téllez, H. H. (2023) · Revista Alergia México · doi:10.29262/ram.v69i2.1088 · Cited by 1
The future of pediatric gene therapy: CRISPR-Cas9, AI, and personalized medicine
Pan, Y., Ding, J., Wang, W., Xu, D., Fan, J., & Zhang, W. (2026) · Pediatric Research · doi:10.1038/s41390-026-05270-3 · Cited by 2
(2022) · Publishing House of the Far Eastern Federal University eBooks · doi:10.24866/7444-5302-2 · Cited by 1
Oyedele, T., Park, R., Morales, K., Jain, M., Sher, L., Vutikullird, A., Isaacs, A., Jepson, B. M., Shoemaker, K., Stanley, A. M., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128304 · Cited by 3
Vaccins COVID-19 : une course contre la montre
Peiffer‐Smadja, N., Rozencwajg, S., Kherabi, Y., Yazdanpanah, Y., & Montravers, P. (2021) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2021.04.006 · Cited by 1
Cross-Country Comparison of COVID-19 Control: Stringency Index, Vaccination, and Variant Effects
Zhou, H., & Ye, Q. (2025) · Disaster Medicine and Public Health Preparedness · doi:10.1017/dmp.2025.10286 · Cited by 1
Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis
Hernández-Porto, M., García, S., Delgado, T., Rodriguez, Y., Aguirre‐Jaime, A., Campos, S., Hernández-Sánchez, C., Lorenzo, C., & Lecuona, M. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.05.065 · Cited by 1
Molina-López, A., Ocón‐Hernández, O., & Baena‐García, L. (2022) · Clínica e Investigación en Ginecología y Obstetricia · doi:10.1016/j.gine.2022.100822 · Cited by 1
SARS-CoV-2 vaccines elicit differential Fc effector functions
Manamela, N. P., Motsoeneng, B. M., Spencer, H., Hermanus, T., Mzindle, N. B., Ayres, F., Makhado, Z., Serage, R., Gray, G., Bekker, L., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113084 · Cited by 4
Magid, A., Hussein, K., Dabaja‐Younis, H., Szwarcwort‐Cohen, M., Almog, R., Mekel, M., Weissman, A., Hyams, G., Gepstein, V., Horowitz, N. A., et al. (2024) · Antibodies · doi:10.3390/antib13030063 · Cited by 1
“In late 2020, when the vaccine for SARS-CoV-2 was introduced [23], HCWs in our institution were offered a serology test since many of them were hesitating before vaccination and had the assumption that they were already positive.”
BackgroundDemaret, J., Corroyer-Simovic, B., Alidjinou, E. K., Goffard, A., Trauet, J., Miczek, S., Vuotto, F., Dendooven, A., Huvent‐Grelle, D., Podvin, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.08.451426 · Cited by 1
“To further assess the neutralizing activity of sera, retroviral pseudoparticles containing the SARS-CoV2 glycoprotein S (SARS-CoV-2pp) were produced as previously described (4), with a plasmid encoding the human "codon-optimized" sequence of the SARS-CoV-2 glycoprotein Spike (accession number: MN908947).”
MethodMarin, J., Bourgoin, P., Saverna, N., Cartagena, C., Lafforgue, P., Busnel, J., & Balandraud, N. (2025) · Arthritis Research & Therapy · doi:10.1186/s13075-025-03553-4 · Cited by 1
Ebenig, A., Muraleedharan, S., Kazmierski, J., Tödt, D., Auste, A., Anzaghe, M., Gömer, A., Postmus, D., Gogesch, P., Niles, M. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.28.474359 · Cited by 1
“While the predictive value of these animal models remains to be scrutinized, this scenario prompted the scientific community and vaccine developers to carefully evaluate the predisposition of COVID-19 infection for disease enhancement and to avoid induction of TH2biased immunity or non-functional Ab responses by the d…”
BackgroundInfluentialNobelpreis für Medizin und Physiologie 2023 für Grundlagenforschung auf dem Gebiet der mRNA
Rennert, C., & Thimme, R. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2186-7414 · Cited by 1
Yau, Y., Mishra, S., Easterling, M., & Kumar, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-9001-3_31 · Cited by 1
Gallen, C., Dukes, C. W., Aldrich, A. L., Macaisa, L., Mo, Q., Cubitt, C. L., Pilon‐Thomas, S., Giuliano, A. R., Czerniecki, B. J., & Costa, R. L. B. (2022) · Vaccines · doi:10.3390/vaccines10111931 · Cited by 1
Kasztelewicz, B., Skrok, K., Burzyńska, J., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301612 · Cited by 1
Cheung, K. S., Yan, V. K. C., Ye, X., Hung, I. F., Chan, E. W., & Leung, W. K. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16601 · Cited by 1
Smetanová, J., Milota, T., Rataj, M., Hurňáková, J., Zelená, H., & Horváth, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017232 · Cited by 1
On Some Modeling Issues in Estimating Vaccine Efficacy
Gasparini, M. (2024) · Pharmaceutical Statistics · doi:10.1002/pst.2440 · Cited by 1
Extracellular Vesicles for Therapeutic RNA Delivery
Murphy, D. E. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1038 · Cited by 1
Radial nerve motor palsy after COVID vaccination: A case report
Radlberger, R. F., Trinka, E., & Leis, S. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2437_22 · Cited by 1
“In the last years, the outbreak of the severe acute respiratory syndrome coronavirus type 2 (SARS‑CoV‑2) caused a worldwide pandemic [1] which promoted the development of new vaccinations such as the mRNA vaccines Comirnaty® [2] and Spikevax®.”
BackgroundAn AAV-ie based Vaccine effectively protects against SARS-CoV-2 and Circulating VariantsPreprint
Zhao, S., Tan, F., Ke, J., Yang, J., Lin, C.-B., Wang, H., & Zhong, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.19.444889 · Cited by 1
Vaccine Nanotechnology for the Prevention of Infectious Diseases
Sontakke, S., Sharma, P. C., Worsham, R., Kadur, K., Bhargavi, C., & Morebise, O. (2023) · Springer eBooks · doi:10.1007/978-3-031-49933-3_4 · Cited by 1
Recent Advances in Drugs and Vaccines for COVID-19
Tang, M., Yao, X., Tian, F., Jiang, M., & Yang, J. (2021) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2021/v33i2031106 · Cited by 1
COVID‐19 vaccination in patients with multiple sclerosis: what you need to know – a review
Mahmoudi, F., Mirmosayyeb, O., Shaabani, E., Ghaffary, E. M., & Nelson, F. M. (2024) · Health Science Reports · doi:10.1002/hsr2.70119 · Cited by 1
Tazi, A. (2025) · médecine/sciences · doi:10.1051/medsci/2025129 · Cited by 1
Assessing Vaccine Attitudes: A Cross-Sectional Study In Hyderabad, India
Noor, S., Afroze, J., Afshi, S. S., et al. (2024) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2024.160414 · Cited by 1
Díaz, F. J., & Toro-Montoya, A. I. (2022) · Medicina y Laboratorio · doi:10.36384/01232576.596 · Cited by 1
Cheng, C., Hung, H., Lee, J., Huang, P.-W. D., Gu, P., Lai, Y. H., Wang, Y., Wu, T., Lee, C., Wu, T.-J., et al. (2022) · Vaccines · doi:10.3390/vaccines10111827 · Cited by 1
The impact of T7 RNA polymerase class II pause sites on mRNA therapeutics
Li, L., Wang, X., Yan, Q., Gateway, C. G., Meter, B. V., Damase, T. R., Liang, Y., Morales, E., Bueno, M. T. D., McRae, E. K. S., et al. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000123 · Cited by 1
Nanomaterials for Therapeutic Nucleic Acid Delivery
Du, S., Cheng, J. K. J., & Dong, Y. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_100 · Cited by 2
Proregenerative MicroRNAs to Repair the Damaged Heart
Olianti, C., & Giacca, M. (2025) · European Cardiology Review · doi:10.15420/ecr.2025.34 · Cited by 2
Irala, S., Hamid, S., Penayo, E., Michel, F., Couto, P., Vázquez, C., Ortega, M. J., Domínguez, C., Battaglia, S., Horoch, M. V., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.015 · Cited by 2
Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai
Shetty, A., Chatterjee, G., Rajpal, S., Srivastava, T., Gardi, N., Mirgh, S. P., Gokarn, A. G., Punatar, S. B., Shetty, N., Joshi, A. D., et al. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/2449068 · Cited by 1
SARS-CoV-2 infection and vaccination elicit distinct pharyngeal mucosal B cell responses in children
Xu, Q., Shi, L., Wang, L., Cheung, F., Kotekar, A., Koroleva, G., Rice, E., Apps, R., Lack, J., Martens, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72996-3 · Cited by 1
Genomic chronicle of SARS-CoV-2: a mutational analysis with over 1 million genome sequences
Uğurel, O. M., Ata, O., & Turgut‐Balik, D. (2021) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2106-8 · Cited by 4
Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours
Yuile, A., Wei, J., McKelvey, K. J., Colvin, E. K., Zakarya, R., Stoner, S. P., Jagadeesan, A., Yunus, M., de Silva, H. C., Gilson, J., et al. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05258-9 · Cited by 1
“Opportunistically, the COVID-19 pandemic accelerated the development and global rollout of mRNA (BNT162b2, mRNA-1273) and adenoviral DNA-based (ChAdOx1) vaccines [15, 16], which use similar platforms as cancer vaccines.”
The changing landscape of infections in the lung transplant recipient
Lum, J., & Koval, C. E. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001060 · Cited by 2
Vaccination history in covıd 19 cases: Observational study
DOĞAN, A. S., Karakök, T., Gezer, Y., & Değermenci, S. (2022) · Medical Science · doi:10.54905/disssi/v26i121/ms109e2157 · Cited by 1
Zengeni, M. M., & Briggs, N. N. (2023) · Cureus · doi:10.7759/cureus.40626 · Cited by 1
Roederer, A. L., Li, C. J., Lim, E., Cao, Y., Ronsard, L., Lingwood, D., Canaday, D. H., Gravenstein, S., & Balazs, A. B. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116954 · Cited by 4
Interstitial drug delivery system: Physiological basis and (pre)clinical progress
Zhao, A., Tang, Y., Shi, X., & Fan, W. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114275 · Cited by 1
Pan, Z., Jiang, L., Chen, Y., Peng, H., Liu, Y., Zheng, X., He, Y., Liu, Y., Wang, Y., Zhang, X., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01099-25 · Cited by 1
Sheen, J. K., Haushofer, J., Metcalf, C. J. E., & Kennedy‐Shaffer, L. (2022) · Statistics in Medicine · doi:10.1002/sim.9365
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.